Lexicon Pharmaceuticals
Home
Contact Us
Site Map
About Us
About Us Home
Management Team
Board of Directors
Development Team
Locations
Contact Us
History
Pipeline
Drug Pipeline Home
Our Goal
Therapeutic Areas
Drug Development Team
Clinical Trials
Publications
Discovery
Discovery Home
Discovery Process
Technology
Genome5000
Medicinal Chemistry
Patents
Academic Access
Technology Licensing
Scientific Publications
Alliances
Alliances Home
Current Alliances
Technology Licensing
Careers
Careers Home
Opportunities
Our Culture
Benefits
Community Involvement
The Woodlands
Princeton
Awards and Recognition
News
News Home
Media Inquiries
Investors
Investors Home
Media
Events
Stock Quote
SEC Filings
Annual Reports
Corporate Governance
Request Information
News Home
Media Inquiries
Subscribe
Press Releases
Filter
Display #
5
10
15
20
25
30
50
100
All
01/26/2010
Lexicon to host conference call and webcast to review top-line phase 2 results from diabetes trial
01/19/2010
Phase 2 trial of LX4211 demonstrates significant and rapid improvements in multiple parameters in type 2 diabetic patients
11/23/2009
Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009
11/12/2009
Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome
10/27/2009
Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Third Quarter Financial Results
10/20/2009
Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2009 Financial Results on October 27, 2009
10/14/2009
Lexicon Announces Completion of Public Offering of Common Stock
10/08/2009
Lexicon Announces Pricing of Common Stock in Public Offering
10/07/2009
Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock
09/15/2009
Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients with Type 2 Diabetes
«
Start
Prev
1
2
3
4
5
6
7
8
9
10
Next
End
»
Page 3 of 37